These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 8951786)

  • 1. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
    Barbui T; Finazzi G; Dupuy E; Kiladjian JJ; Brière J
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():149-60. PubMed ID: 8951786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia.
    Barbui T; Finazzi G
    Curr Hematol Rep; 2003 May; 2(3):248-56. PubMed ID: 12901347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary thrombocythemia: new drugs for an evolving disease.
    Balduini CL
    Haematologica; 1992; 77(4):297-301. PubMed ID: 1427439
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of patients with essential thrombocythemia: current concepts and perspectives.
    Briere J; Guilmin F
    Pathol Biol (Paris); 2001 Mar; 49(2):178-83. PubMed ID: 11317966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
    Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
    N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of polycythaemia vera and essential thrombocythaemia.
    Tefferi A; Silverstein MN
    Baillieres Clin Haematol; 1998 Dec; 11(4):769-85. PubMed ID: 10640216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic options for essential thrombocythemia and polycythemia vera.
    Solberg LA
    Semin Oncol; 2002 Jun; 29(3 Suppl 10):10-5. PubMed ID: 12096352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indications for lowering platelet numbers in essential thrombocythemia.
    Barbui T
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):22-5. PubMed ID: 12682878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?
    Barbui T
    Semin Hematol; 2004 Apr; 41(2 Suppl 3):15-7. PubMed ID: 15190518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
    Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
    Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
    Iványi JL; Marton É; Plander M; Szendrei T
    Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When and how to treat essential thrombocythemia.
    Barbui T; Finazzi G
    N Engl J Med; 2005 Jul; 353(1):85-6. PubMed ID: 16000360
    [No Abstract]   [Full Text] [Related]  

  • 14. Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.
    Dombi P; Illés Á; Demeter J; Homor L; Simon Z; Karadi E; Udvardy M; Egyed M
    Eur J Haematol; 2017 Feb; 98(2):106-111. PubMed ID: 27557754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Essential thrombocythemia: conventional therapy].
    Grossi A; Vannucchi AM; Longo G; Rafanelli D; Rossi Ferrini P
    Haematologica; 1991 Jun; 76 Suppl 3():368-70. PubMed ID: 1752534
    [No Abstract]   [Full Text] [Related]  

  • 16. [Primary thrombocythemia: diagnosis and therapy].
    Petrides PE
    Med Klin (Munich); 2006 Aug; 101(8):624-34. PubMed ID: 16896569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.
    Cacciola RR; Di Francesco E; Pezzella F; Tibullo D; Giustolisi R; Cacciola E
    Acta Haematol; 2007; 118(4):215-8. PubMed ID: 18057866
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
    Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin and platelet-lowering agents for the prevention of vascular complications in essential thrombocythemia.
    Michiels JJ
    Clin Appl Thromb Hemost; 1999 Oct; 5(4):247-51. PubMed ID: 10726022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
    Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
    Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.